Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

1.

Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.

Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2014 Jan;105(1):97-104. doi: 10.1111/cas.12319. Epub 2014 Jan 9.

PMID:
24206578
[PubMed - indexed for MEDLINE]
2.

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.

PMID:
21148082
[PubMed - indexed for MEDLINE]
Free Article
3.

CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.

Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L, Lo Coco F.

J Clin Oncol. 2000 Mar;18(6):1295-300.

PMID:
10715300
[PubMed - indexed for MEDLINE]
Free Article
4.

Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.

Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R.

J Clin Oncol. 1998 Jan;16(1):78-85.

PMID:
9440726
[PubMed - indexed for MEDLINE]
Free Article
5.

Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake H, Ohno R.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71.

PMID:
11587370
[PubMed - indexed for MEDLINE]
6.

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P.

Blood. 1998 Oct 15;92(8):2712-8.

PMID:
9763554
[PubMed - indexed for MEDLINE]
Free Article
7.

Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials.

Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Daniel MT, Labarthe Ad, Maarek O, Cassinat B, Adès L, Baruchel A, Degos L, Azoulay E, Dombret H.

Eur J Cancer. 2014 Apr;50(6):1159-68. doi: 10.1016/j.ejca.2013.11.023. Epub 2014 Jan 15.

PMID:
24440088
[PubMed - indexed for MEDLINE]
8.

Long-term survey of outcome in acute promyelocytic leukemia.

Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z.

Chin Med J (Engl). 2000 Feb;113(2):107-10.

PMID:
11775530
[PubMed - indexed for MEDLINE]
Free Article
9.

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA.

Blood. 2010 Dec 16;116(25):5650-9. doi: 10.1182/blood-2010-06-288613. Epub 2010 Sep 21.

PMID:
20858857
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.

Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2012 Nov;103(11):1974-8. doi: 10.1111/j.1349-7006.2012.02390.x. Epub 2012 Sep 18.

PMID:
22834728
[PubMed - indexed for MEDLINE]
11.

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH.

Blood. 2002 Dec 15;100(13):4298-302. Epub 2002 Aug 15.

PMID:
12393590
[PubMed - indexed for MEDLINE]
Free Article
12.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

PMID:
23090499
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.

Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, et al.

Blood. 1995 Mar 1;85(5):1202-6.

PMID:
7858250
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment.

Chou WC, Tang JL, Yao M, Liang YJ, Lee FY, Lin MT, Wang CH, Shen MC, Chen YC, Tien HF.

Leukemia. 1997 Jul;11(7):921-8.

PMID:
9204969
[PubMed - indexed for MEDLINE]
15.

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Sanz MA.

Haematologica. 2010 Mar;95(3):424-31. doi: 10.3324/haematol.2009.013243. Epub 2009 Nov 10.

PMID:
19903674
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.

Ito S, Ishida Y, Oyake T, Satoh M, Aoki Y, Kowata S, Uchiyama T, Enomoto S, Sugawara T, Numaoka H, Suzuki K, Murai K.

Leuk Lymphoma. 2004 Sep;45(9):1783-9.

PMID:
15223636
[PubMed - indexed for MEDLINE]
17.

All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.

Ohno R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, et al.

Leukemia. 1994;8 Suppl 3:S64-9.

PMID:
7808028
[PubMed - indexed for MEDLINE]
18.

All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).

Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Sakamaki H, Tsubaki K, Saito K, Ohno R.

Cancer Chemother Pharmacol. 1997;40 Suppl:S30-5.

PMID:
9272131
[PubMed - indexed for MEDLINE]
19.

Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.

Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA; Spanish Cooperative Group PETHEMA.

Leukemia. 2007 Mar;21(3):446-52. Epub 2007 Jan 4.

PMID:
17205057
[PubMed - indexed for MEDLINE]
20.

[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].

Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.

Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85. Serbian.

PMID:
16296239
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk